公司观点 - 礼来公司首席执行官Dave Ricks批评英国药品定价体系 称英国是欧洲药品定价最差的国家[1] 行业现状 - 英国药品定价政策受到制药行业质疑 可能影响创新药物可及性[1] - 欧洲各国药品定价存在显著差异 英国处于不利地位[1]

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is the Indianapolis-based pharmaceutical giant and is accelerating its dominance in obesity treatments while expanding its global footprint and manufacturing capacity. The company’s obesity drug franchise, led by Mounjaro (tirzepatide), has scaled rapidly beyond the ...

Eli Lilly (LLY) closed at $746.98 in the latest trading session, marking a -1.06% move from the prior day. This change lagged the S&P 500's daily loss of 0.55%. On the other hand, the Dow registered a loss of 0.19%, and the technology-centric Nasdaq decreased by 0.95%. Prior to today's trading, shares of the drugmaker had gained 8.57% outpaced the Medical sector's loss of 0.2% and the S&P 500's gain of 3.64%.The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's ear ...

投资计划 - 公司宣布投资65亿美元在美国德克萨斯州休斯敦建设全新生产设施以扩大其小分子药物产能 重点用于生产实验性口服减肥药orforglipron [1] - 这是公司今年宣布的第二项重大投资计划 此前2月已宣布计划斥资至少270亿美元在美国新建四家制造工厂 [1] - 自2020年以来公司在美国国内生产领域的累计投资已达230亿美元 其余两家工厂选址将在今年公布 预计未来五年内四家工厂全部投入运营 [1] 产能扩张背景 - 美国减肥药需求激增 公司与竞争对手诺和诺德的GLP-1类每周注射药物面临供应紧张局面 [1] - 口服剂型orforglipron被视为公司维持市场主导地位的关键产品 [1] - 新工厂将大幅提升orforglipron规模化生产能力 帮助满足全球数千万肥胖症及2型糖尿病患者治疗需求 [1] 产品优势 - 相比注射剂型 口服药物无需进食或饮水限制 服用更加便利 [1] - 口服剂型不仅能解决产能不足问题 还将进一步拓宽潜在患者群体 [1] - 小分子药物通常以口服片剂形式出现 对患者使用更方便 更易于大规模生产 制造成本相对更低 [2] 战略考量 - 公司扩大在美国产能布局不仅为满足市场需求 也为降低政策不确定性带来的供应链风险 [2] - 此举是对美国总统特朗普最新关税政策威胁的积极回应 特朗普曾表示可能对进口到美国的药品征收关税以推动制药企业将生产环节迁回美国 [2] - 过去十年美国本土药品制造业规模显著萎缩 [2] 生产范围与就业影响 - 休斯敦新工厂将主要生产orforglipron以及其他针对心脏代谢健康、肿瘤学、免疫学和神经科学等领域的小分子药物 [2] - 该项目将为休斯敦地区带来615个全职岗位 包括工程师、科学家、运营人员和实验室技术人员 [2] - 同时在建设过程中创造4000个建筑相关工作岗位 [2]

Key TakeawaysFord (F) has expanded a recall to 4,632 Expedition and Navigator SUVs from the 2020 model year due to a battery junction box circuit board short risk, with two underhood fires reported, though no stop-driving instructions have been issued.Disney+ (DIS) is set to implement another price hike in October, with the ad-supported plan increasing by $2 to $11.99 and the premium no-ads plan rising by $3, reflecting ongoing "streamflation" in the digital entertainment sector.Federal Reserve Chair Jerome ...

The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years. ...

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday. ...

Eli Lilly on Tuesday said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of so-called small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020. Eli Lilly ...

Accessibility StatementSkip Navigation The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS, Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine a ...

每经记者｜陈星 每经编辑｜张海妮 减重药物赛道的较量越来越激烈。 首先是在药物数据上"你来我往"——今年8月，礼来公布ATTAIN-1研究数据，在第72周，礼来在研口服 小分子GLP-1 RA（胰高血糖素样肽-1受体激动剂）药物Orforglipron最高剂量组平均减重12.4kg（降幅 12.4%）。 近期，诺和诺德方面公布了发表在《新英格兰医学杂志》上的口服司美格鲁肽片Ⅲ期试验OASIS 4的结 果。试验结果显示，在64周时，在所有患者依从治疗的情况下，口服司美格鲁肽片25mg组患者实现了 16.6%的平均体重降幅。 其次，MNC（跨国制药企业）也在不断"扫货"GLP-1，随着近日辉瑞宣布以73亿美元收购Metsera，这 一市场的BD（商务拓展）预期和商业化预期都正在被逐步透支。 礼来、诺和诺德"你来我往" 礼来、诺和诺德在GLP-1赛道的竞争愈演愈烈。 礼来公布Orforglipron的Ⅲ期临床研究"ACHIEVE-3"的顶线结果，该结果优于口服司美格鲁肽的结果 后，诺和诺德公布了Ⅲ期试验OASIS 4的结果。在此项为期64周的试验中，口服司美格鲁肽片25mg联合 生活方式干预，在307名肥胖或超重且 ...